Market closedNon-fractional
HCW Biologics/HCWB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About HCW Biologics
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Ticker
HCWB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Miramar, United States
Employees
45
Website
www.hcwbiologics.com
HCW Biologics Metrics
BasicAdvanced
$23M
Market cap
-
P/E ratio
-$0.76
EPS
0.94
Beta
-
Dividend rate
Price and volume
Market cap
$23M
Beta
0.94
Financial strength
Current ratio
0.463
Quick ratio
0.372
Long term debt to equity
94.667
Total debt to equity
94.667
Interest coverage (TTM)
-146.89%
Management effectiveness
Return on assets (TTM)
-47.07%
Return on equity (TTM)
-132.46%
Valuation
Price to revenue (TTM)
5.551
Price to book
2.59
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
-0.764
Growth
Revenue change (TTM)
7.68%
Earnings per share change (TTM)
51.15%
3-year revenue growth (CAGR)
-1.43%
3-year earnings per share growth (CAGR)
-22.50%
What the Analysts think about HCW Biologics
Analyst Ratings
Majority rating from 1 analysts.
HCW Biologics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.1M
-15.38%
Net income
-$7.4M
-30.19%
Profit margin
-672.72%
-17.50%
HCW Biologics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.14
-$0.12
-$0.14
-$0.30
Expected
-$0.14
-$0.15
-$0.13
-$0.14
Surprise
0.00%
-18.18%
7.69%
114.29%
HCW Biologics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for HCW Biologics stock?
HCW Biologics (HCWB) has a market cap of $23M as of July 27, 2024.
What is the P/E ratio for HCW Biologics stock?
The price to earnings (P/E) ratio for HCW Biologics (HCWB) stock is 0 as of July 27, 2024.
Does HCW Biologics stock pay dividends?
No, HCW Biologics (HCWB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next HCW Biologics dividend payment date?
HCW Biologics (HCWB) stock does not pay dividends to its shareholders.
What is the beta indicator for HCW Biologics?
HCW Biologics (HCWB) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell HCW Biologics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.